North America: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Qui Tam Lives To Fight Another Day: What The Eleventh Circuit’s Zafirov Decision Means For The False Claims Act
The False Claims Act’s qui tam provisions are among the federal government’s most important tools for identifying and pursuing alleged fraud involving Medicare, Medicaid, federal health care programs and other government funds. The statute permits a private individual, known as a relator, to bring a False Claims Act action “for the person and for the United States Government” in the name of the government.
United States Healthcare
BI
Buchanan Ingersoll & Rooney PC
Article
FDA Holds Landmark Public Hearing On The Future Therapeutic Use Of Psychedelic Drugs
The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.
United States Healthcare
FH
Foley Hoag LLP
Article
Cipla And Qilu Announce Exclusive U.S. Licensing And Supply Agreement For Pembrolizumab Biosimilar
InvaGen Pharmaceuticals Inc., a Cipla Limited subsidiary, has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the licensing and supply of QL2107, a biosimilar to Merck's KEYTRUDA® (pembrolizumab), in the United States. This collaboration represents the latest in a series of partnering transactions directed to pembrolizumab biosimilar candidates, with Qilu handling development and regulatory registration while Cipla USA manages commercialization.
United States Healthcare
GP
Goodwin Procter LLP
Article
No Surprises Act IDR Portal Overhaul: Key Changes For Providers And Payers
The No Surprises Act's Independent Dispute Resolution process is undergoing a major technology transformation with a new centralized portal for open negotiations. This development introduces standardized procedures for billing disputes between healthcare providers and payers, but also raises critical questions about compliance, system capacity, and whether the portal adequately addresses persistent challenges in payment collection and claim eligibility determination.
United States Healthcare
B
Bracewell
See more

Highlighted Content

Healthcare

Article
Qui Tam Lives To Fight Another Day: What The Eleventh Circuit’s Zafirov Decision Means For The False Claims Act
The False Claims Act’s qui tam provisions are among the federal government’s most important tools for identifying and pursuing alleged fraud involving Medicare, Medicaid, federal health care programs and other government funds. The statute permits a private individual, known as a relator, to bring a False Claims Act action “for the person and for the United States Government” in the name of the government.
United States Healthcare
BI
Buchanan Ingersoll & Rooney PC
Article
FDA Holds Landmark Public Hearing On The Future Therapeutic Use Of Psychedelic Drugs
The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.
United States Healthcare
FH
Foley Hoag LLP
Article
No Surprises Act IDR Portal Overhaul: Key Changes For Providers And Payers
The No Surprises Act's Independent Dispute Resolution process is undergoing a major technology transformation with a new centralized portal for open negotiations. This development introduces standardized procedures for billing disputes between healthcare providers and payers, but also raises critical questions about compliance, system capacity, and whether the portal adequately addresses persistent challenges in payment collection and claim eligibility determination.
United States Healthcare
B
Bracewell
See more

Food and Drugs Law

Article
FDA Holds Landmark Public Hearing On The Future Therapeutic Use Of Psychedelic Drugs
The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.
United States Healthcare
FH
Foley Hoag LLP
Article
Cipla And Qilu Announce Exclusive U.S. Licensing And Supply Agreement For Pembrolizumab Biosimilar
InvaGen Pharmaceuticals Inc., a Cipla Limited subsidiary, has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the licensing and supply of QL2107, a biosimilar to Merck's KEYTRUDA® (pembrolizumab), in the United States. This collaboration represents the latest in a series of partnering transactions directed to pembrolizumab biosimilar candidates, with Qilu handling development and regulatory registration while Cipla USA manages commercialization.
United States Healthcare
GP
Goodwin Procter LLP
See more

Life Sciences, Biotechnology & Nanotechnology

Article
Qui Tam Lives To Fight Another Day: What The Eleventh Circuit’s Zafirov Decision Means For The False Claims Act
The False Claims Act’s qui tam provisions are among the federal government’s most important tools for identifying and pursuing alleged fraud involving Medicare, Medicaid, federal health care programs and other government funds. The statute permits a private individual, known as a relator, to bring a False Claims Act action “for the person and for the United States Government” in the name of the government.
United States Healthcare
BI
Buchanan Ingersoll & Rooney PC
Article
Cipla And Qilu Announce Exclusive U.S. Licensing And Supply Agreement For Pembrolizumab Biosimilar
InvaGen Pharmaceuticals Inc., a Cipla Limited subsidiary, has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the licensing and supply of QL2107, a biosimilar to Merck's KEYTRUDA® (pembrolizumab), in the United States. This collaboration represents the latest in a series of partnering transactions directed to pembrolizumab biosimilar candidates, with Qilu handling development and regulatory registration while Cipla USA manages commercialization.
United States Healthcare
GP
Goodwin Procter LLP
See more

Latest Videos

See more